<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071655</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-09-01(ML25052)</org_study_id>
    <secondary_id>2009-012562-31</secondary_id>
    <nct_id>NCT01071655</nct_id>
  </id_info>
  <brief_title>Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer</brief_title>
  <acronym>SETICC</acronym>
  <official_title>Selecting Treatment in Colorectal Cancer: Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3'UTR and ERCC1-118 to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the capecitabine or
      5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be
      combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal
      cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2010-2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of patients whose disease becomes resectable</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of KRAS status as a molecular marker</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with zero favorable genotype: BVZ + XELIRI.
Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.
Patients with two favorable genotypes : BVZ + FUOX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BVZ + XELOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX</intervention_name>
    <description>BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1
BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly
BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BVZ+XELOX</intervention_name>
    <description>BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent signed

          -  Histological or citological adenocarcinoma confirmation carcinoma on the colon or
             colorectal metastatic or relapsed patients with adenocarcinoma of colon or recto,
             confirmed histologically with metastatic disease

          -  measurable disease (following RECIST criteria)

          -  ECOG ≤ 2

          -  older or equal 18 years old

          -  life expectancy superior to 3 months

          -  Adequate or moderate renal function: renal function (Creatinine clearance &gt; 30mL/min),
             based on Cockroff - Gault.

          -  Potential fertile women negative pregnancy test in serum or urine, 10 days prior the
             first study dose given

          -  Use an adequate contraceptive method

        Exclusion Criteria:

          -  Patients treated previously with Bevacizumab

          -  Non measurable lesion as only disease evidence

          -  Previous chemotherapy treatment for adjuvant or neoadjuvant disease (no metastatic
             (M0), or immunotherapy active/passive for the advance or metastatic disease. It is
             permitted the adjuvant or neoadjuvant treatment it is has finished at least 6 months
             before the initiation of the study drug.If the patient has received an adjuvant
             treatment previously the patient cannot participate if disease progression has been
             confirmed during the treatment or on the 6 months later

          -  Prior radiotherapy is allowed if it has not been administered in the target lesions
             selected for this study, unless progression of said lesions in the irradiated field is
             documented, and as long as treatment has concluded at least 4 weeks before beginning
             the study.

          -  Prior surgical treatment of the disease in stage IV is allowed

          -  Functional dependency

          -  Previous serious adverse events or unexpected to fluoropyrimidine treatment and /o
             patients with proved deficit in dehidropirimidin dehydrogenase (DPD)

          -  Patients classified as &quot;weak or fragile&quot;

          -  Cardiac concomitant present: Symptomatic auriculoventricular arrhythmia history, and /
             cardiac arrhythmias requiring medication or peripheral vascular disease, grade II or
             higher. Furthermore, those patients who have had a myocardial infarction in the year
             prior to beginning the treatment of the study will be excluded.

          -  History of another neoplastic disease during the last five years, with the exception
             of cured basal cell carcinoma of the skin and cervical carcinoma in situ.

          -  History or indications of CNS disease in the physical examination.

          -  History of psychiatric disability that the investigator considers clinically
             significant, which prevents the patient from granting the informed consent or
             interferes with compliance of taking the oral medication.

          -  Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular
             disease: CVA/stoke (≤ 6 months prior to randomisation), myocardial infarction (≤ 6
             months prior to randomisation), unstable angina, New York Heart Association (NYHA,)
             Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring
             medication.

          -  Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome
             or inability to take oral medication.

          -  Patients subjected to organ allograft who require immunosuppressive treatment.

          -  Severe, non-cicatrized osseous fractures, wounds or ulcers

          -  Indications of hemorrhagic diathesis or coagulopathy.

          -  Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant
             diseases.

          -  Any of the following laboratory values:

               1. Absolute neutrophil count (ANC) &lt; 1.5 x 109/l

               2. Platelet count &lt; 100 x 109/l

               3. Hemoglobin &lt; 10 g/dl (it can be transfused to maintain or exceed this level)

               4. International Normalized Ratio (INR) &gt; 1.5

               5. Total bilirubin &gt; 1.5 times the upper limit of normal (ULN)

               6. ALAT, ASAT &gt; 2.5 x ULN or &gt; 5 x (ULN) in the case of hepatic metastases

               7. Alkaline phosphatase &gt; 2.5 x ULN or &gt; 5 x ULN in the case of hepatic metastases
                  or &gt; 10 x ULN in the case of osseous metastases.

          -  Patients subjected to a major surgical procedure, open biopsy or who have had
             significant traumatic lesions within the 28 days prior to beginning the treatment of
             the study or in whom it is foreseen that a major surgical procedure will be necessary
             during the course of the study; fine-needle aspiration within the 7 days prior to
             beginning the treatment of the study.

          -  Current or recent use (within the 10 days prior to beginning the treatment of the
             study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents.
             The use of low doses of warfarin is allowed, with an International Normalized Ratio
             [INR] of &lt; 1.5.

          -  Daily chronic treatment with high doses of aspirin (&gt; 325 mg/day) or non-steroid
             anti-inflammatory medications (which inhibit the platelet function at doses used for
             treating chronic inflammatory diseases).

          -  Patients who have received any drug or agent/procedure under research, i.e., who have
             participated in another clinical trial during the 4 weeks prior to beginning the
             treatment with the medications of the study.

          -  Pregnancy or lactating woman. Woman with reproductive potential unless using an
             effective method of contraception (Postmenopausal woman must have been amenorrheic
             during at least 12 months).

          -  Known hypersensitivity to any of the study drugs or excipients of the Bevacizumab or
             to Chinese hamster ovary cell products or to other recombinant human or humanised
             antibodies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Abad</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Català d'Oncologia.Hospital Universitari Germans Trias i Pujol. Badalona. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>5FU</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

